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The capsular serotype has long been associated with the virulence of Streptococcus pneumoniae. Here we
present an in-depth study of phenotypic and genetic differences between serotype 3 and serogroup 11 S.
pneumoniae clinical isolates from both the general and indigenous populations of Australia. Both serotypes/
groups included clonally unrelated strains with differences in well-known polymorphic virulence genes, such as
nanA and pspA, as demonstrated by multilocus sequence typing and Western blot analysis. Nonetheless, the
serotype 3 strains were consistently and significantly more virulent in mice than the serogroup 11 strains.
Despite extensive genomic analysis, noncapsular genes common to one serotype/group but not the other were
not identified. Nevertheless, following the conversion of a serotype 11A isolate to serotype 3 and subsequent
analysis in an intranasal infection model, it was evident that both capsular and noncapsular factors determine
the virulence phenotype in mice. However, it appears that these noncapsular factors vary from strain to strain.
Streptococcus pneumoniae (the pneumococcus) is a formida-
ble pathogen, being responsible for a broad spectrum of dis-
eases, including pneumonia, meningitis, bacteremia, and otitis
media (OM), and it accounts for more deaths worldwide than
any other single pathogen (48). In Australia, the overall rate of
invasive pneumococcal disease (IPD) in the indigenous popu-
lation is over 4 times the rate seen in nonindigenous Austra-
lians (54). Furthermore, chronic suppurative OM, which is
normally rare in developed countries, is present in remote
Aboriginal communities at 10 times the rate defined as a major
public health concern by the World Health Organization (9).
Not only do children living in these communities suffer the
highest rates of tympanic membrane perforation in the world,
but 80% are estimated to suffer from some degree of OM-
related hearing impairment (45).
Significant research on the pneumococcus has already been
undertaken, but there are still many unanswered questions due
to the complex nature of its pathogenicity. The polysaccharide
capsule that surrounds the pneumococcus and determines the
serotype, of which there are more than 90, is the most well-
established virulence factor. Certain serotypes have been
shown to have a higher association with disease or carriage
than others (7, 19, 20, 60). In addition, a number of conserved
virulence proteins, including neuraminidase A (NanA), pneu-
molysin (Ply), autolysin (LytA), and pneumococcal surface
proteins A and C (PspA and PspC), have been widely charac-
terized and shown to be critical in pathogenesis (29, 50). How-
ever, these are only a subset of potential virulence factors. Like
other pathogens, such as Haemophilus influenzae, another
common cause of invasive disease and OM, S. pneumoniae has
a pangenome (23, 24). Core genes, which are conserved across
pneumococcal strains, represent only 70 to 80% of the ge-
nome, and a gene pool of over 5,000 orthologous clusters is
estimated to be available to this naturally transformable or-
ganism from other pneumococcal strains and related bacterial
species (23). An understanding of the role in virulence of these
noncore genes, which are generally found in regions of the
genome known as regions of diversity or accessory regions
(ARs), is only just beginning to emerge. The majority of stud-
ies on pneumococcal ARs to date have focused on IPD (5, 13,
59). In addition, although there have been numerous epidemi-
ological studies highlighting the problem of OM in remote
Australian Aboriginal communities (33, 38, 45), very limited
molecular analysis of isolates from these communities has been
performed. Accordingly, this study aimed to characterize a
range of isolates from geographically and temporally diverse
Australian Aboriginal communities and the general population
using a variety of molecular techniques with a view to identi-
fying common genes or ARs potentially associated with but not
necessarily limited to OM.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used in this
study are listed in Table 1. Pneumococci were routinely grown in THY (Todd-
Hewitt broth supplemented with 1% Bacto yeast extract), serum broth (SB)
(10% [vol/vol] donor horse serum in nutrient broth), or brain heart infusion
(BHI) broth or on blood agar (BA) plates at 37°C in 95% air and 5% CO2.
Gentamicin and optochin were added at a concentration of 5 g/ml where
appropriate. For storage, S. pneumoniae was grown in SB supplemented with
glycerol to 30% and stored at 80°C. Pneumococcal opacity-phase morphology
was determined on THY-catalase plates, as described previously (65). Strains
were confirmed as S. pneumoniae by optochin sensitivity, while serotype-specific
capsule production was confirmed by Quellung reaction using diagnostic antisera
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obtained from Statens Serum Institut, Copenhagen, Denmark. The level of
capsule expression was determined by the uronic acid assay. Escherichia coli One
Shot TOP10 chemically competent cells (Invitrogen, Victoria, Australia) were
grown in Luria-Bertani (LB) broth or on LB agar plates, in the presence of
ampicillin (Amp) at 50 g/ml where appropriate.
Bacterial transformation. Pneumococci were transformed using complete
transformation medium (CTM) (17, 40). For cloning and transformation of E.
coli, the TOPO TA cloning kit (Invitrogen) with pCR2.1-TOPO and One Shot
TOP10 chemically competent cells were used, according to the manufacturer’s
instructions. LB-Amp plates containing 1.6 mg of X-Gal (5-bromo-4-chloro-3-
indolyl--D-galactopyranoside) were used for selection.
DNA manipulations. All oligonucleotide primer sequences are available on
request. Chromosomal DNA for genome sequencing and PCR was extracted and
purified as described previously (55). PCRs were carried out in an Eppendorf
Mastercycler (Eppendorf, Hamburg, Germany) using a final volume of either 25
or 50 l. Standard reactions were performed using Taq DNA polymerase (Roche
Diagnostics, Basel, Switzerland), according to the manufacturer’s instructions.
The Expand long-template or high-fidelity PCR system (Roche Diagnostics) was
TABLE 1. Pneumococcal strains used in this study
Strain Description Source and/or reference
D39 Serotype 2 4
TIGR4 Serotype 4 Tim Mitchell, University of Glasgow,
Scotland (1)
WU2 Serotype 3 David Briles, University of Alabama
(6)
WCH206 Serotype 3 (ST180) OM isolate WCH
WCH207 Serotype 3 (ST180) OM isolate WCH
WCH208 Serotype 3 (ST458) OM isolate WCH
WCH209 Serogroup 11 sinusitis isolate WCH
WCH210 Serogroup 11 sinusitis isolate WCH
WCH211 Serogroup 11 (ST3020) sinusitis isolate WCH
WCH212 Serogroup 11 sinusitis isolate WCH
WCH213 Serogroup 11 (ST62) OM isolate WCH
Menzies1 Serotype 11A (ST3021) nasopharyngeal isolate Menzies
Menzies2 Serotype 11A nasopharyngeal isolate Menzies
Menzies3 Serotype 11A nasopharyngeal isolate Menzies
Menzies4 Serotype 11A nasopharyngeal isolate Menzies
Menzies5 Serotype 11A (ST662) nasopharyngeal isolate Menzies
Menzies6 Serotype 11A nasopharyngeal isolate Menzies
Menzies7 Serotype 11A nasopharyngeal isolate Menzies
Menzies8 Serotype 11A nasopharyngeal isolate Menzies
Menzies9 Serotype 11A nasopharyngeal isolate Menzies
Menzies10 Serotype 11A nasopharyngeal isolate Menzies
Menzies11 Serotype 3 (ST458) nasopharyngeal isolate Menzies
Menzies12 Serotype 3 (ST458) OM isolate Menzies
Menzies13 Serotype 3 nasopharyngeal isolate Menzies
Menzies14 Serotype 3 (ST458) OM isolate Menzies
Menzies15 Serotype 3 nasopharyngeal isolate Menzies
Menzies16 Serotype 3 nasopharyngeal isolate Menzies
Menzies17 Serotype 3 (ST458) OM isolate Menzies
WCH43 Serotype 4 (ST205) blood isolate WCH
2663 Serotype 11A (ST3019) lung isolate Michael Watson, Path West, Perth,
Western Australia, Australia
3518 Serotype 11A (ST62) Path West
1 Serotype 1 (ST304) nasopharyngeal isolate MSHR
4 Serotype 1 (ST227) nasopharyngeal isolate MSHR
1861 Serotype 1 (ST3079) blood isolate MSHR
4496 Serotype 1 (ST3018) blood isolate WCH
3773 Serotype 15B (ST199) Path West
4104 Serotype 19A (ST199) Path West
WCH16 Serotype 6A WCH
WCH18 Serotype 6B WCH
WCH50 Serotype 6 WCH
WCH33 Serotype 8 WCH
WCH36 Serotype 14 WCH
WCH39 Serotype 14 WCH
WCH60 Serotype 14 WCH
WCH61 Serotype 14 WCH
WCH38 Serogroup 19 WCH
WCH64 Serogroup 19 WCH
WCH65 Serogroup 19 WCH
EF3030 Serotype 19F University of Alabama
WCH67 Serogroup 23 WCH
WCH68 Serogroup 23 WCH
WCH69 Serogroup 23 WCH
WCH101 Serogroup 23 WCH
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used when high-fidelity PCR was required. DNA sequencing reactions were
carried out using the BigDye Terminator v3.1 cycle sequencing kit (Applied
Biosystems, California).
MLST. S. pneumoniae isolates were subjected to multilocus sequence typing
(MLST) using the method and primer sequences described previously (15) and
classified according to the pneumococcal MLST database (http://spneumoniae
.mlst.net/).
DNA microarray analysis. DNA microarray experiments were performed on
whole-genome S. pneumoniae PCR arrays based on TIGR4 and R6 annotations
(26, 61). Array slides were obtained from the Bacterial Microarray Group at St.
George’s, University of London. The array design is available in BG@Sbase
(accession no. A-BUGS-14; http://bugs.sgul.ac.uk/A-BUGS-14) and also Array-
Express (accession no. A-BUGS-14). Briefly, S. pneumoniae DNA (10.5 g in
100 l) was digested with Sau3A1 or RsaI (New England BioLabs [NEB],
Beverly, MA) and cleaned using a Qiagen MinElute PCR purification kit. There-
after, 20 l of purified digest was labeled for each dye (Alexa Fluor 555 and
Alexa Fluor 647) per slide, using the Genisphere Array 900 DNA labeling kit for
microarrays (Genisphere, Hatfield, PA) according to the manufacturer’s instruc-
tions. Slides were incubated overnight in a dark, humidified chamber at 65°C,
washed in a 3-step process (15 min with 2 SSC [1 SSC is 0.15 M NaCl plus
0.015 M sodium citrate]–0.03% [vol/vol] SDS at 65°C, 15 min with 1 SSC at
room temperature [RT], and 15 min with 0.2 SSC at RT), and dried. Slides
were scanned using a GenePix 4000B scanner (Molecular Devices), and images
were acquired using GenePix Pro 6.0 software (Axon).
PCR-based subtractive hybridization. PCR-based subtractive hybridization
(3) was performed using the Clontech PCR-Select bacterial genome subtraction
FIG. 1. Alleles of nanA, pspA, and pspC detected in serogroup 3 and 11 strains. Alleles were identified for nanA, pspA, and pspC by sequencing
or PspA family typing, in accordance with reports by King et al. (32), Hollingshead et al. (25), and Iannelli et al. (27), respectively. Proteins are
shown in proportion to their approximate size. NanA is represented in lilac. The NanA identified in WCH206 is identical to the NanA present in
D39. The other nanA alleles have a 15-bp insertion (indicated by a dark purple box) and a 180-bp deletion (indicated by a black line), which have
been previously described in the nanA alleles of other pneumococcal strains (32). In addition, one of the alleles, which is found in both serotype
3 and serogroup 11, has a 500-bp region of diversity at the 5 terminus, which is indicated by pink, and has also been previously described (32).
PspA and PspC proteins are categorized as described by Hollingshead et al. (25) and Iannelli et al. (27), respectively. The color scheme of Iannelli
et al. has been used. Homologous sequences are represented by boxes of the same color. Dark gray/black, signal peptide; other shades of gray,
random coil; green, proline-rich region; blue, anchor; other colors, -helix. The clade-determining regions of PspA (25) are indicated by white dots.
Lines indicate absence of DNA.
FIG. 2. Capsular polysaccharide production by type 3 isolates. Cap-
sular polysaccharide produced by the indicated strains was quantitated
by uronic acid assay, as described in Materials and Methods. Data are
the means  standard deviations (SD) from five independent experi-
ments. *, P  0.05; **, P  0.01 (unpaired t test).
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kit (Clontech, Palo Alto, CA), with the exception that the primary hybridization
incubation time was increased to 8 h. Ligations were performed following the
manufacturer’s instructions using T4 DNA ligase and buffer (NEB). PCRs were
performed with a hot start, using Taq polymerase and 1.6 reaction buffer as
outlined in the kit manual. Secondary PCR products were used for cloning.
Next-generation sequencing. Sequencing and genome assembly were per-
formed by Geneworks (Thebarton, Adelaide, Australia) with chromosomal DNA
prepared as described above, using an Genome Analyzer II (Illumina, San
Diego, CA) and Lasergene 8 software (DNASTAR Inc., Madison, WI).
Bioinformatics. The pneumococcal genomes and BLAST programs available
through the Kyoto Encyclopedia of Genes and Genomes (www.genome.jp/kegg/)
and National Center for Biotechnology Information (http://www.ncbi.nlm.nih
.gov/) were used in the analysis of sequencing data. The ClustalW program
available through the website of the European Bioinformatics Institute (EBI)
(http://ebi.ac.uk/Tools) was used to align multiple sequences.
Protein analysis. Bacteria were lysed and subjected to SDS-PAGE, as de-
scribed previously (41). Separated proteins were electroblotted onto nitrocellu-
lose (Protran, Melbourne Australia) as described previously (41). After transfer,
the membrane was probed with specific polyclonal mouse or rabbit antisera at a
dilution of 1/3,000 and then reacted with blotting-grade goat anti-mouse or goat
anti-rabbit IgG–alkaline phosphatase (AP) conjugates (Bio-Rad Laboratories).
The hemolytic activity of pneumococcal lysates was determined as described
previously (51), using phosphate-buffered saline (PBS)-washed human erythro-
cytes.
Virulence and pathogenesis studies. All animal experiments used outbred 5-
to 6-week-old CD-1 (Swiss) mice and were approved by the Animal Ethics
Committee of the University of Adelaide. For intraperitoneal (i.p.) and
pneumonia/sepsis models, opaque variants were cultured in SB to approxi-
mately 1  108 CFU/ml and diluted in sterile SB to the appropriate challenge
dose. The actual challenge doses were determined retrospectively by plating
on BA with or without antibiotic selection, as appropriate. Mice in the
pneumonia/sepsis study were anesthetized with Nembutal (pentobarbitone
sodium; Rhone-Merieux) and challenged intranasally (i.n.), as previously
described (36, 39). For survival studies, mice were monitored closely over a 3-
to 4-week period following challenge for signs of disease, and the survival
time of each mouse was recorded. For the capsule switch study, mice were
sacrificed by CO2 asphyxiation, and nasal wash, ear wash, nasal tissue, lung,
blood, and brain samples were taken. The nasal wash and blood perfusion
techniques have been described previously (36). The ear wash was performed
by puncturing both tympanic membranes with a pipette tip and washing the
ear cavities with a combined 100 l of sterile trypsin buffer (0.5% trypsin in
PBS). The nasal tissue, lungs, and brain were removed and homogenized in
1 ml PBS using a Precellys 24 homogenizer (Bertin Technologies, Pessac,
France) according to the manufacturer’s instructions. Enumeration of bacte-
ria in the various samples was performed as previously described (36, 39). For
i.n. colonization studies, transparent-phase bacteria were grown in THY to
mid-logarithmic phase. i.n. challenge without anesthesia, sample processing,
and enumeration of bacteria were performed as previously described (41).
Accession numbers. Fully annotated microarray data have been deposited in
the BG@Sbase and ArrayExpress databases (accession number E-BUGS-126).
Sequencing data have been deposited in the NCBI Sequence Read Archive
(accession number SRX026162).
RESULTS
Strain selection. For the purposes of this study, a number of
clinical S. pneumoniae isolates belonging to serotypes 3 and
11A were obtained from the Menzies School of Health Re-
search (Menzies), Darwin, Australia, and the Women’s and
Children’s Hospital (WCH), North Adelaide, Australia (Table
1). The Menzies isolates were derived from a variety of indig-
enous communities in temporally and geographically diverse
locations. Serotype 3 is frequently isolated from the ear dis-
charges of indigenous children with acute OM with perforation
of the tympanic membrane yet is less frequently isolated from
nasal swabs in asymptomatic members of the same population
(34). In addition, this serotype has a high association with OM
worldwide (20, 21, 58), and isolation of serotype 3 strains from
OM patients has reportedly risen following the introduction of
7-valent pneumococcal conjugate vaccine (PCV7) (42). Sero-
type 3 is a less frequent cause of IPD, but nevertheless, cases
of type 3 IPD have a high fatality rate (19, 22, 60). In Europe,
Japan, and North America, sequence type 180 (ST180) is the
major clone within serotype 3 (7, 28, 42, 60), whereas in South
Africa and Ghana, ST458 is more dominant (35, 46). The
second serotype examined, 11A, is a common nasopharyngeal
isolate in Aboriginal children but is rarely isolated from the
middle ear (34). All serotype 11A isolates used in this study are
of nasopharyngeal origin (Table 1). Serotype 11A has been
associated with OM in other communities, including in Aus-
tralia (18, 64), but is generally not as common as serotype 3
(20, 21, 53). Even though it also has a low association with IPD
(19), serotype 11A clinical isolates of ST62 have been shown to
have a high case-fatality rate in patients with underlying med-
ical conditions (60).
In addition to the Menzies isolates, the serotype 3 and se-
rogroup 11 isolates obtained from WCH are from the general
population and have a well-documented clinical history (Table
1). We could not determine whether the WCH serogroup 11
isolates were serotype 11A because the available antiserum
used in this study is only serogroup 11 specific. The serotype 2
strain D39 (4), the serotype 4 strain TIGR4 (1), and the sero-
type 3 strain WU2 (6), which have been used in numerous
published studies, were also included in some experiments
(Table 1).
Preliminary characterization of serotype 3 and serogroup 11
clinical isolates. The serotype 3 and serogroup 11 clinical iso-
lates from Menzies and WCH had hitherto been uncharacter-
ized, and so it was important to determine their pathogenicity
profiles in order to establish any correlation between human
disease and our mouse models. To this end, we first compared
the expression profiles of well-characterized virulence proteins
PspA, PspC, Ply, LytA, and NanA with that in the highly
virulent serotype 2 S. pneumoniae strain D39 by Western blot-
ting, using polyclonal antisera (see Fig. S1 in the supplemental
material). Western blot analysis showed no apparent difference
in size or intensity using anti-LytA and anti-Ply polyclonal sera
for all serotype 3 and serogroup 11 strains. Furthermore, a
FIG. 3. Virulence and nasopharyngeal colonization of selected serotype 3 and serogroup 11 isolates. (A) Survival of CD-1 mice in the
pneumonia/sepsis model. Groups of 10 mice were inoculated with 1.5  107 to 4  107 CFU of the indicated strains. The median survival time
for each group is indicated by a horizontal bar. (B) Survival of CD-1 mice following i.p. injection of groups of 10 mice with either 5  102 CFU
(serotype 3) or 1  107 CFU (serogroup 11) of bacteria. The median survival time for each group is indicated by a horizontal bar. (C) Number
of bacteria in the nasopharynx (nasopharyngeal tissue and nasal wash) over a 7-day period following intranasal inoculation with 1  107 to 2 
107 CFU/mouse. Groups of 20 mice were inoculated without anesthesia, and 5 mice were euthanized per time point, survival permitting. The
median number of bacteria in the nasopharynx for each strain is represented by a horizontal bar. The broken line represents the limit of detection
(40 CFU). (D) Long-term colonization after intranasal challenge was determined by plating nasopharyngeal washes from the mice that were still
alive at 4 weeks after intranasal challenge (panel A).
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Ply-specific hemolysis assay using human erythrocytes showed
there were no differences in specific hemolytic activity between
strains of the same serotype (data not shown). The differences
observed in the Western blots for PspA, PspC, and NanA were
further investigated in selected strains by PspA family typing
(63), PCR, or sequencing of the pspA, pspC, and nanA genes,
and the results are summarized in Fig. 1. The alleles identified
for these three genes have been previously described by Hol-
lingshead et al. (25), Iannelli et al. (27), and King et al. (32),
respectively. Interestingly, the serogroup 11 strains revealed
more variable results than the serotype 3 strains, although
some strains, such as Menzies1 and Menzies3, exhibited iden-
tical protein profiles. The serotype 3 strains could be divided
into two distinct groups (one comprising WCH206 and
WCH207 and the other the remainder) based on their Western
blot profiles.
Selected isolates were subsequently characterized by multi-
locus sequence typing (MLST) (14) based on their Western
blot profiles. Serotype 3 strains that exhibited identical protein
profiles in the Western blot analysis were found to have iden-
tical STs; WCH206 and WCH207 were ST180, whereas
WCH208, Menzies11, Menzies12, Menzies14, and Menzies17
were ST458. WU2 was typed as ST378 (as found by Poolman
et al. [52]). As predicted from the divergent protein profiles,
the serogroup 11 strains WCH211, WCH213, Menzies1, and
Menzies5 all belong to unrelated STs (ST3020, ST62, ST3021,
and ST662, respectively). WCH211 and Menzies1 are the first
reported isolates of their respective STs.
TABLE 2. Statistical analysis of survival data
Model Strain
P valuea
WU2 WCH206 WCH207 Menzies11 Menzies17
Pneumonia/sepsis WU2 0.0007 0.0172 0.0185 0.0003
WCH206 0.0007 NS NS 0.0355
WCH207 0.0172 NS NS 0.003
MSHR11 0.0185 NS NS 0.0039
MSHR17 0.0003 0.0355 0.003 0.0039
WCH211 NS 0.0004 0.0023 0.0049 0.0004
WCH213 NS 0.0004 0.0023 0.0049 0.0004
Menzies1 NS 0.0004 0.0023 0.0049 0.0004
Menzies5 NS 0.0004 0.0023 0.0049 0.0004
i.p. WU2 NS 0.0355 NS 0.0015
WCH206 NS 0.0147 NS 0.0147
WCH207 0.0355 0.0147 NS NS
MSHR11 NS NS NS NS
MSHR17 0.0015 0.0147 NS NS
WCH211 0.0298 0.0302 0.0114 0.0412 0.0123
WCH213 0.0002 0.0004 0.0001 0.0008 0.0002
Menzies1 NS NS NS NS 0.0168
Menzies5 0.0021 0.0028 0.0025 0.0078 0.0027
a Survival time data were analyzed using the Mann-Whitney U test (two tailed). NS, not significant (P 	 0.05).
TABLE 3. Statistical analysis of nasopharyngeal colonization data
Day Serogroup 11strain
P valuea
WU2 WCH206 WCH207 Menzies11 Menzies17
1 WCH211 0.0345 NS NS 0.0097 NS
WCH213 0.0112 0.0200 0.0159 0.0097 0.0200
Menzies1 NS NS NS 0.0259 NS
Menzies5 NS NS NS 0.0259 NS
2 WCH211 NS NS NS NS NS
WCH213 0.0112 0.0112 0.0200 0.0112 0.0317
Menzies1 0.0112 0.0112 0.0112 0.0112 0.0079
Menzies5 0.0112 0.0112 0.0112 0.0112 0.0079
3 WCH211 NS 0.0311 NS NS NS
WCH213 NS 0.0178 NS NS NS
Menzies1 NS 0.0097 NS NS NS
Menzies5 0.0317 0.0097 NS NS NS
4 WCH211 NS NS NS NS NS
WCH213 NS NS NS NS NS
Menzies1 NS NS NS NS NS
Menzies5 NS NS NS NS NS
a Survival time data were analyzed using the Mann-Whitney U test (two tailed). NS, not significant (P 	 0.05).
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The colonies of the ST180 strains WCH206 and WCH207
were larger and more homogenous in size than those of the
other serotype 3 strains following overnight growth on BA. No
differences in colony morphology were evident between sero-
group 11 strains. Capsular polysaccharide production in
WCH206, WCH207, Menzies11, Menzies17, and WU2 was
compared using the uronic acid assay. There was no significant
difference in capsule production between isolates of the same
ST. However, WCH206 and WCH207 produced statistically
significantly less capsular polysaccharide than Menzies11 and
Menzies17 (Fig. 2). WU2 produced significantly less capsule
than Menzies17 but not Menzies11.
We subsequently evaluated selected serotype 3 and sero-
group 11 strains for their virulence characteristics in mouse
pneumonia/sepsis and intraperitoneal (i.p.) (sepsis) models
(Fig. 3A and B). Statistical analysis of survival data is shown in
Table 2. Serotype 3 strains were highly virulent in the pneu-
monia/sepsis model, with the exception of WU2, which killed
fewer than 50% of the mice and was significantly less virulent
than all of the other serotype 3 strains. Menzies17 was also
more virulent than all the other serotype 3 strains, including
Menzies 11, which belongs to the same ST (Fig. 3A and Table
2). In contrast, serogroup 11 strains were essentially avirulent
in the pneumonia/sepsis model, and survival times were signif-
icantly different from those of all the serotype 3 strains except
WU2. In the i.p. model, they killed fewer than 50% of mice
when injected at very high doses (1  107 CFU/mouse), and
survival times for three of the strains were significantly greater
than those for mice given only 5  102 CFU of the serotype 3
strains (Fig. 3B and Table 2). Strains were also compared in an
intranasal (i.n.) colonization model (Fig. 3C). Interestingly,
serogroup 11 strains were isolated more frequently and (for
most strains) in significantly greater numbers from the naso-
pharynxes of mice on days 1 and 2 after i.n. challenge than the
serotype 3 strains (Fig. 3C and Table 3). Longer-term coloni-
zation was also explored by performing nasopharyngeal washes
on surviving mice in the pneumonia/sepsis study (Fig. 3A) at 4
weeks postinoculation. Both serotypes/groups were found to
be capable of longer-term colonization of the nasopharynx
(Fig. 3D).
Microarray analysis and PCR-based subtractive hybridiza-
tion of ST180 and ST458 strains. The existence of two clonally
unrelated groups within the serotype 3 clinical isolates pre-
sented an attractive opportunity for assessment of commonal-
ity and/or differences in the overall genetic compositions of
these strains. First, we compared the genomes of WCH208
(ST458), Menzies12 (ST458), Menzies13, and Menzies15,
which displayed identical protein profiles to one another, by
DNA microarray analysis using slides representing the ge-
nomes of TIGR4 and R6 (a rough derivative of D39). No
differences were detectable, consistent with the protein profiles
and ST data. Similarly, microarray and genome sequence anal-
yses of strains from the ST180 lineage have shown them to
exhibit few genetic differences, even when isolated from dif-
ferent continents (11, 23). Next, we compared the genomes of
selected ST180 (WCH206) and ST458 (Menzies17) strains.
The results showed that 3 open reading frame (ORFs) were
present in WCH206 but absent in Menzies17, while 15 ORFs
were detectable in Menzies17 but absent in strain WCH206
(see Table S1 in the supplemental material). Similarly,
genomic comparisons between serogroup 11 strains were
made, and several genes were detected to be either present or
absent in these comparisons (see Table S1 in the supplemental
material). We subsequently carried out genomic comparisons
of the serotype/group 3 and 11 strains to detect any genes that
were unique to one serotype. However, no noncapsular gene
which was present in all isolates of one serotype but absent in
every isolate of the other was identified.
FIG. 4. Genomic islands in S. pneumoniae Hungary19A-6 and G54 containing the putative cellobiose PTS system. The figure is based on the
genome maps of Hungary19A-6 (nucleotides [nt] 1784704 to 1794633, Refseq NC_010380) and G54 (nt 1630647 to 1637715, Refseq NC_011072).
The indicated ORFs are annotated as follows: sph1921/spg1693, hypothetical protein; sph1922/spg1693, hypothetical protein; sph1923, sulfatase-
modifying factor 1 (spg1694, hypothetical); sph1924, sulfatase; sph1925, PTS system cellobiose-specific IIC component (spg1995, hypothetical;
spg1696, hypothetical); sph1926/spg1697, lichenan-specific phosphotransferase enzyme IIA component; sph1927/spg1698, lichenan-specific phos-
photransferase enzyme IIB component; sph1928, hypothetical protein (spg1699, hypothetical; spg1700, hypothetical); sph1929/spg1701, lichenan
permease IIC component; sph1930/spg1702, putative ROK family protein. Genes are shaded according to their KEGG pathway function, with
black indicating membrane transport and white indicating an unassigned pathway. WCH206 possesses the same island as Hungary19A-6.
Menzies17 and Menzies11 have the same deletion as G54 but do not have the two single-base-pair insertions causing frameshifts and premature
stop codons.
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One of the limitations of DNA microarray analysis is that it
gives no information on genes which may be present in the
strains tested but absent on the array. In order to overcome
this, a PCR-based subtractive hybridization method (3) was
adapted to detect genes present in both ST180 and ST458 but
absent in R6 and TIGR4. Using this procedure, we identified
serotype 3 capsule genes (effectively a positive control) and the
IIA and IIB components of a putative cellobiose phospho-
transferase system (PTS1), which was sequenced by Shen et al.
in a study identifying pneumococcal ORFs absent in the
TIGR4 and R6 genomes (57). Interestingly, the pneumococcus
has a second cellobiose PTS (PTS2), which is also part of a
larger mobile genetic element, and its components were iden-
tified during a signature-tagged mutagenesis virulence gene
screen using a chinchilla middle ear infection model, suggest-
ing a role in OM (8).
Forbes et al. reported that PTS1 belongs to a mobile genetic
element consisting of 10 genes (16). A putative choline sulfa-
tase gene in this region in ATCC 700669 (Spain 23F ST81
lineage) was also reported by Croucher et al. (10). We com-
pared the genomic organization with those annotated for G54
(12) and Hungary19A-6 (J. Craig Venter Institute). The PTS
was found to be associated with a genomic island harboring a
ROK (regulator, ORF of unknown function, kinase) family
protein and a putative sulfatase with an associated modifying
factor, as well as hypothetical proteins (Fig. 4). The ROK
family protein does not have the DNA binding motif charac-
teristic of repressors in this family. We agree with the obser-
vation of Forbes et al. that the organization of this island is well
conserved (16), but G54 has a deletion of about 2.5 kb, includ-
ing the putative sulfatase gene, as well as parts of the sulfatase-
modifying factor and the last gene of the putative cellobiose
PTS. The same deletion is apparent in the serotype 3 strains
Menzies11 and Menzies17 (isolates of ST458), but WCH206
(an isolate of ST180) carries the full genomic island. The se-
quence of G54 suggests that it also has two insertions in two
genes of the PTS operon, resulting in frameshifts and prema-
ture stop codons, but these insertions are not present in the
island sequences of Menzies11 or Menzies17. The absence of
the sulfatase in the ST458 isolates explains why genes down-
stream of the cellobiose PTS were not detected by PCR-based
subtractive hybridization. The gene of the ROK family protein
is located on a restriction fragment of over 3.6 kb, which is well
outside the optimal size for PCR-based subtractive hybridiza-
tion (2).
Distribution of the genomic island carrying a putative cel-
lobiose PTS. WU2 and the serogroup 11 isolates were analyzed
by PCR to determine whether they carried PTS1 or not (see
Table S2 in the supplemental material). Interestingly, WU2 did
not, but all four serogroup 11 strains did. We also examined
the distribution of PTS1, as well as the sulfatase and PTS2, by
both bioinformatic analysis utilizing publically available pneu-
mococcal genomes and PCR analysis of clinical isolates with a
range of serotypes and virulence potentials (see Table S2 in the
supplemental material). Only one strain appeared to possess
neither PTS1 nor PTS2, with the majority of strains possessing
both. Only 3 out of the 4 serogroup 11 isolates possessed PTS2.
Most isolates carrying PTS1 also carried the sulfatase.
Genome sequence comparison. In order to determine
whether there were additional ARs missed by PCR-based sub-
tractive hybridization, the genome of Menzies17 was se-
quenced and aligned against the published genome of OXC141
(serotype 3, ST180; ftp://ftp.sanger.ac.uk/pub/pathogens/spn/).
The average coverage depth was 14.68, and sequence gaps of
over 100 bp in the alignment represented approximately 6.3%
of the OXC141 genome. Although serotype 3 ST180 isolates
are known to carry additional genes apart from the PTS1 AR
which are absent in TIGR4 and D39, none common to Men-
zies17 were detected (23, 57). This indicates that the PCR-
based subtractive hybridization methodology enabled efficient
identification and isolation of major genetic differences be-
tween isolates.
Impact of capsular serotype and genetic background on
pathogenesis. Previous studies have indicated the importance
of additional genetic factors to serotype in pneumococcal dis-
ease (31, 43, 56, 59). Indeed, the difference in survival between
WU2 and the other serotype 3 isolates in the pneumonia/sepsis
model (Fig. 3A) is indicative of the importance of genotype.
However, it has also been demonstrated that serotype influ-
ences the behavior of genotype in mouse in vivo models (30, 47,
62). As the isolates of the two groups in this study have distinct
behaviors in our mouse models and there are no additional
factors to distinguish the two apart from the capsule loci, the
role of serotype for our particular isolates was further ex-
plored. For this purpose, one of the serotype 11A strains from
a remote Aboriginal community (Menzies5) was capsule
switched with a serotype 3 capsule by transformation with a
PCR product comprising the capsule locus from WCH206.
This strain was designated Menzies53, and type 3 capsule pro-
duction was confirmed by the Quellung reaction. In addition,
loss of reactivity to serogroup 11 antiserum was observed.
There was no significant difference in serotype 3 capsular poly-
saccharide production between Menzies53 and the donor
strain WCH206 as assessed by the uronic acid assay. The mu-
tant also exhibited a growth profile identical to that of Men-
zies5 and WCH206 (data not shown). Colonization of various
tissues by the three strains in the pneumonia/sepsis model over
a 3-day period was investigated (Fig. 5). Acquisition of the
serotype 3 capsule by Menzies53 reduced nasopharyngeal col-
onization significantly on all three days but did not increase
bacterial numbers recovered in any other niche (ears, lungs,
blood, or brain) relative to those of Menzies5 at any time point.
WCH206 was isolated in significantly higher numbers than
Menzies53 from the ears (day 3), lungs (day 2), blood (day 2),
FIG. 5. Ability of the capsule switch mutant to colonize various niches of the mouse. Groups of mice were anesthetized and inoculated i.n. with
approximately 107 CFU/mouse of WCH206, Menzies53, or Menzies5. Numbers of pneumococci in various host niches were determined for 5 mice
from each group after 1, 2, or 3 days, as described in Materials and Methods. The median number of bacteria is indicated by a black horizontal
bar, and the limit of detection is indicated by a broken line, which is 40 CFU in the nasopharynx, lungs, blood, and brain and 4 CFU in the ears.
The Mann-Whitney U test (two tailed) was used to analyze data. *, P  0.05; **, P  0.01.
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and brain (day 2 but not day 1). Therefore, although serotype
clearly influences the ability of the ST662 isolate to colonize
the nasopharynx, the ST180 genotype is fitter than the ST662
genotype in various niches of the pneumonia/sepsis model for
serotype 3.
DISCUSSION
Serotype 3 S. pneumoniae is an important OM pathogen
worldwide, including in remote Australian Aboriginal commu-
nities (20, 34, 52). Despite the burden of pneumococcal OM in
these communities, there has been very little molecular char-
acterization of isolates. In this study, we have analyzed isolates
from remote communities using a variety of techniques, includ-
ing Western blot analysis, a hemolysis assay, a capsular poly-
saccharide assay, MLST, and murine virulence and coloniza-
tion models. Although the isolates were acquired from diverse
locations, the serotype 3 isolates were found to be from the
ST458 clonal cluster, which is unrelated to the ST180 clone
that normally dominates in developed countries (7, 28, 42, 60).
Interestingly, this ST has also been seen to dominate over
ST180 in South Africa and Ghana, which are also socioeco-
nomically disadvantaged (35, 46). Both ST458 and ST180 iso-
lates are highly virulent in our mouse models, in contrast to the
serogroup 11 isolates. However, despite observed differences
in the epidemiology of serogroup 11 isolates and behavior in
our mouse model, the capsule switch experiment performed in
this study further underscores the importance of noncapsular
factors in disease. This does not mean that serotype is unim-
portant. In the capsule switch study, Menzies53 was clearly
attenuated in the nasopharynx in comparison to Menzies5.
Kadioglu et al. also found that their serotype 3 capsule switch
variant of D39 and A66 (serotype 3 capsule donor) colonized
the nasopharynx at lower numbers than wild-type D39 over a
24-h period (30). Furthermore, although extensive analyses
were conducted using DNA microarrays, PCR-based subtrac-
tive hybridization, and Illumina sequencing, we could not iden-
tify a specific factor common to the serotype 3 ST180 and
ST458 isolates but absent in the 4 unrelated serogroup 11
isolates. In addition, host factors are likely to influence geno-
type. The prevalence of the ST458 clone over ST180 suggests
that it may be better adapted for the microenvironmental
niches encountered in remote Aboriginal communities.
In this study, we have shown that PCR-based subtractive
hybridization can be adapted to complement DNA microarray
hybridization by identifying genes absent on the microarray
slide. A previously discovered but uncharacterized putative
cellobiose PTS (PTS1) common to ST180 and ST458 was iden-
tified through this technique, which constitutes part of a
genomic island harboring a putative ROK family protein and a
putative sulfatase with an associated modifying factor. The
putative cellobiose utilization AR had initially been noted to
be more common in invasive isolates (16), but as with other
pneumococcal ARs (5), when a larger number of isolates were
characterized, this relationship could not be confirmed. How-
ever, the wide distribution of the AR and the putative role of
its genes both suggest potential importance. Furthermore, the
apparent involvement of a second pneumococcal cellobiose
PTS (PTS2) in OM (8) also suggests that a role for PTS1 in
OM is worthy of exploration. It is also interesting to note that
the ST662 isolate Menzies5, which was less fit than WCH206
(ST180) in various niches of the pneumonia/sepsis model in a
serotype 3 background, and WU2 (ST378), which was less
virulent than ST180 and ST458 isolates in the same model,
possess only one of the PTSs, while ST180 and ST458 isolates
possess both.
In this study, despite extensive molecular analyses, we could
not identify any ARs that are unique to OM isolates. It is likely
that different ARs contribute to virulence in unrelated strains
and that virulence of a given strain is a function of multiple
ARs. The impact of any combination of ARs could be influ-
enced by other factors, including redundancy of ARs and cap-
sular type, as well as host factors. Overall, there appears to be
no simple answer to why one strain is more prevalent in disease
or carriage than another, and the ability of an isolate to cause
disease is likely to reflect a complex mix of serotype, genotype,
and host factors.
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